Both short- and long-acting GLP-1 drugs equally reduced food intake and appetite in 50 diabetes patients, and the effect wasn't driven by slower stomach emptying or GI side effects — pointing to a central brain mechanism.
No gastric emptying linkWeight loss and appetite reduction from GLP-1 drugs were not related to slower stomach emptying or GI side effects — the effect is brain-mediated
What the researchers found
Both GLP-1 receptor agonists produced comparable effects on:
- Macronutrient and energy intake (equally reduced)
- Body weight loss
- Appetite reduction
The key mechanistic finding was that weight loss and appetite reduction were NOT related to delayed gastric emptying or GI side effects (p > 0.05 for both). This challenges the common assumption that GLP-1 drugs reduce appetite mainly by slowing stomach emptying or causing nausea.
Both drugs improved exocrine pancreas function (faecal elastase and serum beta-carotin increased), suggesting GLP-1 drugs may benefit pancreatic enzyme output.
Liraglutide specifically increased serum lipase by 18.3 U/L (p = 0.0001), while lixisenatide did not. This lipase elevation is clinically relevant because lipase rises can indicate pancreatic stress, though in this case it was associated with improved pancreatic markers overall.
Why it matters
Understanding how GLP-1 drugs reduce appetite is important for optimizing their use. This study shows the appetite effect is not simply caused by nausea or slow stomach emptying, suggesting a central brain mechanism. The improved pancreatic function is an unexpected bonus.
The numbers in context
N=50; 10 weeks; equal weight/appetite reduction; liraglutide lipase +18.3 U/L (p=0.0001); no gastric emptying/GI side effect link
How the study worked
Randomized trial of 50 participants assigned to lixisenatide or liraglutide for 10 weeks. Appetite, satiety, macronutrient intake, GI symptoms, gastric emptying, and pancreatic function markers were assessed at baseline and after treatment.
Who was studied
50 adults with type 2 diabetes (human, randomized trial)
What this study cannot tell us
With only 50 patients, the study is relatively small. The 10-week duration may not capture longer-term differences. The study was in type 2 diabetes patients and may not apply to non-diabetic weight management. Specific food preference changes were assessed but not detailed in the abstract.
How to read the evidence
Moderate evidence from a well-designed randomized controlled trial with 50 participants over 10 weeks. The study directly tested and refuted the gastric emptying hypothesis with statistical rigor. Limited by small sample size and single-center design, but the mechanistic finding is clear and clinically relevant.
When this study was published
Published in 2021. The mechanistic insight — that GLP-1 appetite suppression is brain-mediated, not stomach-mediated — remains an important reference point as newer GLP-1 drugs enter the market.
The bigger picture
The mechanism debate around GLP-1 drugs matters for clinical practice. If appetite suppression were mainly caused by nausea, then patients who don't get nauseous shouldn't lose weight — but they do. This study confirms that appetite reduction is a central (brain-mediated) effect independent of GI side effects. This insight supports the neuroimaging evidence that GLP-1 drugs reshape brain appetite circuits and explains why they work even after GI side effects resolve. It also challenges the practice of using nausea as a proxy for drug efficacy.
Questions still open
- If appetite suppression isn't mediated by gastric emptying, should clinicians stop using anti-nausea medications that might not affect weight loss outcomes?
- Does the lipase elevation with liraglutide indicate pancreatic stress or improved pancreatic function?
- Would these findings differ in non-diabetic obesity patients where pancreatic function is presumably normal?
Common questions
If GLP-1 drugs don't work by slowing digestion, how DO they reduce appetite?
Does no nausea mean the drug isn't working?
Read the original research
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.
Diabetes, obesity & metabolism, 23(10), 2344-2353
Citation
Quast, Daniel R; Nauck, Michael A; Schenker, Nina; Menge, Björn A; Kapitza, Christoph; Meier, Juris J. (2021). Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.. Diabetes, obesity & metabolism, 23(10), 2344-2353. https://doi.org/10.1111/dom.14477